Clin2
NCT07791901Possibly a fitNot yet recruiting

Psilocybin therapy for demoralization in advanced cancer

Advanced CancerDemoralizationExistential DistressPsychological Distress

Part of Cancer clinical trials.

This study tests whether psilocybin (a hallucinogen) combined with psychological support can help reduce feelings of hopelessness and loss of meaning in people with advanced cancer. It aims to see if this treatment can improve emotional well-being and quality of life.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
60 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be at least 18 years old.
  • You must have advanced cancer (Stage III, IV, or metastatic) or, if Stage II, your doctor confirms it is advanced or hard to treat.
  • You need to have significant demoralization or distress as shown by a specific questionnaire.
  • You must be able to attend at least 2 preparation sessions, 1 dosing session, and 2 integration sessions.
  • You must speak and understand English well enough for therapy and questionnaires.
  • If you can become pregnant, you must have a negative pregnancy test and use effective birth control.
  • You need a responsible adult to stay with you for at least 12 hours after the dosing session.
  • You cannot have active psychosis, mania, or serious suicidal thoughts or attempts recently.
  • You cannot have unstable heart, liver, kidney, or blood sugar problems, or uncontrolled seizures.
  • You must not be taking certain medications that would interfere with the study drug.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06818994Recruiting· Phase 1
Psilocybin therapy for low mood in advanced cancer

This trial tests if a medicine called psilocybin, given with talk therapy, can safely help people with advanced cancer who feel very demoralized. Demoralization is a deep sense of hopelessness or loss of meaning. The goal is to see if this treatment can improve your emotional well-being.

Kingston, Ontario
NCT06200155Recruiting· Phase 2
Psilocybin therapy for advanced cancer patients with anxiety or depression

This trial tests whether a drug called psilocybin, given with therapy, can help people with advanced cancer who are feeling anxious or depressed. You must have a stable cancer and be willing to travel to Houston for treatment.

Houston, Texas
NCT05398484Recruiting· Phase 2/Phase 3
Psilocybin therapy for advanced cancer-related anxiety

This trial studies whether psilocybin (with support and therapy) can reduce anxiety in people with advanced cancer. It may help with distress and quality of life, while the study team monitors safety closely.

Aurora, Colorado
NCT05403086Recruiting· Phase 2
Psilocybin for distress in people with serious, life-limiting illness

This Phase 2 study tests whether psilocybin therapy can reduce deep distress (“demoralization”) in people receiving palliative (comfort-focused) care. It may help with mood and well-being, but you must meet safety and medication requirements to join.

Greenbrae, California
NCT07063862Recruiting· Phase 3
Psychedelic microdose for emotional distress in advanced illness

This trial tests whether very low doses of psilocybin (a psychedelic substance) can help reduce emotional distress in people with a life-limiting illness. If you are receiving palliative care and feeling anxious or depressed, this study might offer a way to explore a new treatment option.

Brampton, Ontario
NCT06001749Recruiting· Phase 2
Psilocybin for cancer pain study

This trial tests whether psilocybin (a psychedelic drug) can help with severe cancer pain. You may qualify if your pain is high despite strong medications and you are willing to be monitored closely.

Boston, Massachusetts

Hear when a new Advanced Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.